ATXS
Astria Therapeutics Inc

11,112
Mkt Cap
$710.14M
Volume
521,252.00
52W High
$12.72
52W Low
$3.56
PE Ratio
-5.78
ATXS Fundamentals
Price
$12.45
Prev Close
$12.44
Open
$12.55
50D MA
$10.18
Beta
1.15
Avg. Volume
3.67M
EPS (Annual)
-$1.68
P/B
5.09
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Bailard Inc. Buys New Shares in Astria Therapeutics, Inc. $ATXS
Bailard Inc. acquired a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Astria Therapeutics (NASDAQ:ATXS) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS
Astria Therapeutics (NASDAQ:ATXS - Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the...
MarketBeat·7d ago
News Placeholder
Astria Therapeutics (NASDAQ:ATXS) Lowered to "Neutral" Rating by Cantor Fitzgerald
Cantor Fitzgerald lowered Astria Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Wednesday...
MarketBeat·7d ago
News Placeholder
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their...
PR Newswire·8d ago
News Placeholder
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics (ATXS) delivered earnings and revenue surprises of -34.15% and -95.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the...
Business Wire·8d ago
News Placeholder
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of "Hold" by Brokerages
Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has earned an average rating of "Hold" from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. One...
MarketBeat·12d ago
News Placeholder
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the...
Business Wire·14d ago
News Placeholder
Astria Therapeutics (ATXS) Expected to Announce Quarterly Earnings on Wednesday
Astria Therapeutics (NASDAQ:ATXS) will be releasing its Q3 2025 earnings before the market opens on Wednesday, November 12. (View Earnings Report at...
MarketBeat·14d ago
News Placeholder
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final...
Business Wire·20d ago

Latest ATXS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.